Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis.
Compare the QuantiFERON-TB Gold In-Tube (QFT) assay and the tuberculin skin test (TST) in bladder cancer patients receiving high dose BCG therapy (BCG patients). BCG patients and healthy visitors, both exposed to tuberculosis, were screened with a TST and QFT. QFT-TST correlation was excellent in visitors, but poor in BCG patients. BCG therapy predicted a positive TST (p<0.001) but not a positive QFT (p=0.35). The management of BCG patients was impacted, by measuring the QFT.